產(chǎn)品屬性：
產(chǎn)品名稱 | Vasonatrin Peptide (VNP) (TFA) |
規(guī)格 | 500 μg、1 mg、5 mg |
貨號 | EY-01Y11974 |
Cas No.: N/A
別名: N/A
化學(xué)名: N/A
分子式: C126H199N36O38S3F3
分子量: 2979.39
溶解度: N/A
儲存條件: -20°C, away from moisture
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway[1][2][3].Vasonatrin Peptide (VNP) markedly enhances adiponectin mRNA expression, as well as protein secretion, however, suppresses IL-6 production in mature adipocytes. In addition, VNP significantly increases the intracellular levels of cGMP. The effects of VNP are mimicked by 8-br-cGMP, whereas inhibits by HS-142-1, or KT-5823[2].Vasonatrin peptide (100 μg/kg; i.v. ; 10 min before reperfusion) attenuates myocardial ischemia-reperfusion injury in diabetic rats[3].[1]. Wei CM, et al. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest. 1993;92(4):2048-2052. [2]. Chen BY, et al. Vasonatrin peptide, a new regulator of adiponectin and interleukin-6 production in adipocytes. J Endocrinol Invest. 2011;34(10):742-746. [3]. Shi Z, et al. Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Am J Physiol Heart Circ Physiol. 2015;308(4):H281-H290.
特別提醒公司產(chǎn)品僅供科研使用
